viewC4X Discovery Holdings PLC

C4X says drug discovery alliance with Evotec will help reduce operational costs

Clive Dix, chief executive at C4X Discovery Holdings (LON:C4XD) talks to Proactive Investors after the AIM-listed pharma firm  entered into a multi-target, risk-sharing alliance with Germany's Evotec AG with whom the company already had a collaboration agreement.

"We have moved a step closer to a partnership. We now get a much  deal in terms of the costs of what we do with them. For that they get a small level of ownership" he explains, adding the alliance will see a minimum of three projects active at any point in time.

Dix also commented on the £5mln fund raise the company recently completed.

"That will help fund the programmes we are currently running," he says, "when we get these programmes running with Evotec, we will have eight moving at a rate that will surprise people when we announce the next milestone. We are very excited. We expect within the next year to move some of these programmes significantly".

Quick facts: C4X Discovery Holdings PLC

Price: 18 GBX

Market: AIM
Market Cap: £21.46 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of C4X Discovery Holdings PLC named herein, including the promotion by the Company of C4X Discovery Holdings PLC in any Content on the Site, the...


C4X Discovery CEO welcomes start of Indivior trial and outlines new...

C4X Discovery PLC's (LON:C4XD) Chief Executive Clive Dix speaks to Proactive London about the start of clinical trials of a treatment for opioid dependence. The phase I, single ascending dose trial of the company’s Orexin-1 antagonist, C4X_3256, should be completed by the end of the year. Dix...

on 25/8/20

2 min read